By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Catabasis Pharmaceuticals, Inc. 

161 First Street, Suite 1A

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-349-1971 Fax: 617-273-2637


SEARCH JOBS


Industry
Pharmaceutical






Company News
Catabasis Pharmaceuticals, Inc. To Present At The Wedbush PacGrow Healthcare Conference 8/4/2015 10:45:36 AM
Catabasis Pharmaceuticals, Inc. Will Present The CAT-2000 Program Of SREBP Modulators For Hyperlipidemias At The Kern Lipid Conference 7/28/2015 10:34:22 AM
Catabasis Pharmaceuticals, Inc. And UT Southwestern Medical Center Enter Into A Sponsored Research Agreement For CAT-2000 Series In Serious Lipid Disorders 7/27/2015 10:19:05 AM
Catabasis Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 7/6/2015 7:37:51 AM
Catabasis Pharmaceuticals, Inc. Announces Closing Of Initial Public Offering 7/1/2015 11:08:58 AM
Catabasis Pharmaceuticals, Inc. Shares Surge In Nasdaq Debut; Upsizes to Grab $60M in IPO 6/25/2015 10:57:28 AM
Massachusetts Debuts Three Biotech IPOs for $235M As Market Roars 6/22/2015 7:06:04 AM
Catabasis Pharmaceuticals, Inc. Initiates Movedmd, A Phase I/II Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 6/17/2015 9:11:13 AM
Catabasis Pharmaceuticals, Inc. To Present Data For Hypercholesterolemia Product Candidate, CAT-2054, At The National Lipid Association Scientific Sessions 6/9/2015 11:08:29 AM
Catabasis Pharmaceuticals, Inc. Announces Preliminary Phase 1 Data For Hypercholesterolemia Product Candidate CAT-2054 6/4/2015 9:02:09 AM
123456
//-->